The authorisation is issued for a period of three years and may be renewed for an identical period on application by the authorisation holder to the Director General of the Agence nationale de sécurité du médicament et des produits de santé, no later than six months before its expiry date.
Any renewal of authorisation is examined under the same conditions as the initial authorisation, and after transmission to the Agence nationale de sécurité du médicament et des produits de santé of the report referred to in Article R. 1161-25.